卵巢癌女性主流化基因检测中的患者决策辅助工具:一项前瞻性队列研究
在SIGNPOST研究招募框架内开展队列研究,纳入东北伦敦癌症网络的高级别非黏液性上皮性卵巢癌女性,比较简短与详细决策辅助工具(DA)的满意度、可读性、理解度、情绪健康及偏好。详细DA在满意度(86% vs 58%,p<0.001)、信息量合适(76.79% vs 49.12%,p<0.001)和理解度(p<0.001)上优于简短DA,情绪结局无统计学显著差异;74%偏好详细DA,24%偏好简短DA。正在治疗、复发及年龄较大的女性偏好简短DA。
要点
- 详细DA较简短DA提高满意度(86% vs 58%,p<0.001)和信息量合适度(76.79% vs 49.12%,p<0.001)。
- 详细DA与简短DA在情绪结局上无统计学显著差异,74%患者偏好详细DA。
- 正在治疗(coef=0.603,95%CI 0.165-1.041,p=0.007)、复发(coef=0.493,95%CI 0.065-0.92,p=0.024)及年龄较大(coef=0.042,95%CI 0.017-0.066,p=0.001)的女性偏好简短DA。
核心结论
- 较长的DA在卵巢癌患者中满意度更高,且不增加情绪困扰;年龄较大及正在治疗/复发的女性偏好较少信息,缓解期患者偏好较长DA。
研究设计与样本
- 在SIGNPOST研究(ISRCTN: 16988857)招募框架内开展的前瞻性队列研究,纳入东北伦敦癌症网络(NELCN)人群中接受肿瘤门诊评估的高级别非黏液性上皮性卵巢癌女性,患者评估简短和新的详细DA后由癌症临床医生进行主流化基因检测。
主要发现
- 患者平均年龄66岁(四分位距11),85%为白种英国人,74%认为DA对决策有帮助/有用。
- 详细DA较简短DA满意度更高(86% vs 58%,p<0.001),信息量合适比例更高(76.79% vs 49.12%,p<0.001),理解度改善(p<0.001)。
- 简短DA与详细DA在情绪结局(担心/忧虑/安心/心烦)上无统计学显著差异;74%患者偏好详细DA,24%偏好简短DA。
- 正在治疗(相关系数=0.603;95%CI 0.165-1.041,p=0.007)、复发(相关系数=0.493;95%CI 0.065-0.92,p=0.024)及年龄较大(相关系数=0.042;95%CI 0.017-0.066,p=0.001)的女性偏好简短DA。
- ethnicity不影响结局或对长/短DA的总体偏好。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate patient preference for short (gist) or detailed/extensive decision aids (DA) for genetic testing at ovarian cancer (OC) diagnosis. DESIGN: Cohort study set within recruitment to the Systematic Genetic Testing for Personalised Ovarian Cancer Therapy (SIGNPOST) study (ISRCTN: 16988857). SETTING: North-East London Cancer Network (NELCN) population. POPULATION/SAMPLE: Women with high-grade non-mucinous epithelial OC. METHODS: A more detailed DA was developed using patient and stakeholder input following the principles/methodology of IPDAS (International Patients Decision Aids Standards). Unselected patients attending oncology clinics evaluated both a pre-existing short and a new long DA version and then underwent mainstreaming genetic testing by a cancer clinician. Appropriate inferential descriptive and regression analyses were undertaken. MAIN OUTCOME MEASURES: Satisfaction, readability, understanding, emotional well-being and preference for long/short DA. RESULTS: The mean age of patients was 66 years (interquartile range 11), and 85% were White British ethnicity. Of the participants, 74% found DAs helpful/useful in decision-making. Women reported higher levels of satisfaction (86% versus 58%, p < 0.001), right amount of information provided (76.79% versus49.12%, p < 0.001) and improved understanding (p < 0.001) with the long DA compared with the short DA. There was no statistically significant difference in emotional outcomes (feeling worried/concerned/reassured/upset) between 'short' and 'long' DA; 74% of patients preferred the long DA and 24% the short DA. Patients undergoing treatment (correlation coefficient (coef) = 0.603; 95% CI 0.165-1.041, p = 0.007), those with recurrence (coef = 0.493; 95% CI 0.065-0.92, p = 0.024) and older women (coef = 0.042; 95% CI 0.017-0.066, p = 0.001) preferred the short DA. Ethnicity did not affect outcomes or overall preference for long/short DA. CONCLUSIONS: A longer DA in OC patients has higher satisfaction without increasing emotional distress. Older women and those undergoing treatment/recurrence prefer less extensive information, whereas those in remission preferred a longer DA.
引用
- Sobocan M, Chandrasekaran D, Sideris M, et al. Patient decision aids in mainstreaming genetic testing for women with ovarian cancer: A prospective cohort study. BJOG. 2023. PMID: 37752678. doi:10.1111/1471-0528.17675
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。